GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2025)
GH Research's (GHRS) quarterly Depreciation & Amortization (CF) came in at $88000.0 in Q4 2025, up 12.82% year-on-year from $78000.0 in Q4 2024, and down 1.12% quarter-over-quarter from $89000.0 in Q3 2025.
GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
GH Research's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $88000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 12.82% year-over-year to $88000.0 in Q4 2025; TTM through Dec 2025 was $335000.0, a 6.35% increase from a year earlier, with the FY2025 full-year figure at $335000.0, up 6.35% from the prior year.
- Depreciation & Amortization (CF) declined to $88000.0 in Q4 2025 per GHRS's latest filing, from $89000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $89000.0 in Q3 2025 and bottomed at $1000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $77500.0 (2023), against an average of $51550.0.
- Across the five-year window, Depreciation & Amortization (CF) soared 1000.0% in 2022 and dropped 5.0% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $9000.0 in 2021, then soared by 44.44% to $13000.0 in 2022, then jumped by 500.0% to $78000.0 in 2023, then changed by 0.0% to $78000.0 in 2024, then climbed by 12.82% to $88000.0 in 2025.
- Per Business Quant, the three latest GHRS Depreciation & Amortization (CF) figures stand at $88000.0 (Q4 2025), $89000.0 (Q3 2025), and $82000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | 88,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 88,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Sep 30, 2023 | 80,000.00 |